The Hub for Disease-Specific Clinical Information

Pegilodecakin Plus Anti–PD-1 Therapy for Renal Cell Carcinoma

By: Cordi Craig
Posted: Wednesday, December 5, 2018

The addition of pegilodecakin, a pegylated recombinant human interleukin-10, to anti–PD-1 therapy appears to improve response rates and durability over anti–PD-1 therapy alone in patients with advanced renal cell carcinoma. The study results were presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich (Abstract 1130O).

Pegilodecakin reduces the tumor inflammatory processes, stimulates the activation and expansion of tumor antigen–specific CD8-positive T cells, and promotes immunosurveillance by expanding effector memory T cells, explained Nizar M. Tannir, MD, FACP, of The University of Texas MD Anderson Cancer Center, Houston, and colleagues.

Among 353 patients from a phase I/Ib dose-escalation and dose-expansion study, 37 pretreated individuals with renal cell carcinoma received pegilodecakin with pembrolizumab (n = 8) or nivolumab (n = 29). Patient responses from both groups were pooled and assessed using immune-related response criteria.

The disease control rate of the pooled pegilodecakin plus anti–PD-1 therapy group was 85%. The authors observed a 1-year overall survival rate of 89% and an overall response rate of 41% among the pooled participants. Patients who received the higher dose of pegilodecakin (20 mg/kg) plus nivolumab or pembrolizumab reported more toxicity, including grade 3 and 4 anemia (n = 10), thrombocytopenia (n = 7), and hypertriglyceridemia (n = 6). Grade 3 or 4 anemia or thrombocytopenia did not occur among those treated with the lower dose of pegilodecakin (10 mg/kg).

“These preliminary findings support further studies of pegilodecakin with anti–PD-1 therapies,” the authors concluded.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.